Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study

Najar, Imtiyaz Ahmed; Masoodi, Shariq Rashid; Mir, S. A.; Bhat, Moomin Hussain; Patyar, Rakesh Raman; Patyar, Sazal

doi:10.4103/ijph.ijph_1070_22

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, it was found that administering 25 mg of empagliflozin daily for a period of 3 months, along with triple drug therapy (metformin, teneligliptin, and glimepiride), resulted in significant improvement in the quality of life of patients suffering from type 2 diabetes mellitus with hypertension. The study reported improvements in emotional/mental health and physical health [ 98 ]. Not just diabetic patients, but non-diabetic patients with heart failure with reduced ejection fraction (HFrEF) also reported improvements in their quality of life after being administered empagliflozin [ 99 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Zandifar,

Panahi,

Badrfam

et al. 2024

BMC Psychiatry

View full text Add to dashboard Cite

Background Major depressive disorder is one of the most common psychiatric disorders, which is associated with a high disease burden. Current treatments using antidepressants have limitations, so using medication with neuromodulating and anti-inflammatory properties alongside them could be helpful. In a clinical trial, we studied the effectiveness of empagliflozin, a blood sugar-lowering drug, as an adjunctive therapy to reduce the severity of depression symptoms. Methods A number of outpatients with moderate to severe depression (Hamilton Depression Rating Scale (HDRS) > = 17) who were not under related medication or had not taken medication for at least the last two months, had an age range of 18–60 years and had written informed consent to enter the study (N = 90) were randomly divided into two groups receiving placebo or empagliflozin (10 mg daily) combined with citalopram (40 mg daily) based on permuted block randomization method in an 8-week randomized, double-blind, placebo-controlled clinical trial. They were evaluated using the HDRS in weeks 0, 4, and 8. Results HDRS scores were equal to 28.42(± 3.83), 20.20(± 3.82), and 13.42(± 3.42) in the placebo group during weeks 0,4, and 8, respectively. These scores were 27.36(± 3.77), 13.76(± 1.40), and 7.00(± 1.13), respectively, for the group treated with empagliflozin. Compared to the control group, patients treated with empagliflozin using repeated-measures ANOVA showed greater improvement in reducing the severity of depression symptoms over time (p value = 0.0001). Conclusions Considering the promising findings in this clinical trial, further study of empagliflozin as adjunctive therapy in MDD with larger sample sizes and longer follow-ups is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%